The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Return On Capital Employed Overview: Sunesis Pharmaceuticals
During Q2, Sunesis Pharmaceuticals's (NASDAQ: SNSS) reported sales totaled $0.00. Despite a 9.43% in earnings, the company posted a loss of $6.34 million. Sunesis Pharmaceuticals collected $120.00 thousand in revenue during Q1, but reported earnings showed a $5.80 million loss.Why ROCE Is Significant
Benzinga · 09/03 13:55
The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Benzinga · 09/03 11:55
Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that the Company will present at two upcoming virtual investor conferences.Wells Fargo 2020 Virtual Healthcare Conference Date: Thursday, September 10 Time: 2:00 PM Eastern TimeOppenheimer
GlobeNewswire · 09/03 11:00
Sunesis Pharmaceuticals to reverse split shares 1:10
To regain compliance with Nasdaq's $1 minimum bid price listing requirement, Sunesis Pharmaceuticals ([[SNSS]] -32.0%) will execute 1:10 reverse stock split within the split ratio range of 1:2 and 1:12, after the
Seekingalpha · 09/02 17:49
Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-10 reverse stock split, effective as of 5:00 p.m. Eastern
GlobeNewswire · 09/02 16:48
Seeking Alpha Catalyst Watch
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stock
Seeking Alpha - Article · 08/28 18:30
Sunesis Pharmaceuticals Q2 EPS $(0.06), Inline
Sunesis Pharmaceuticals (NASDAQ:SNSS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 33.33 percent increase over losses of $(0.09) per share from the same period last
Benzinga · 08/11 20:26
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)
Benzinga · 08/11 12:20
Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it will host a conference call on Tuesday, August 11th, 2020 at 4:30 p.m. Eastern Time to discuss corporate updates and financial r
GlobeNewswire · 08/04 11:00
Sunesis Announces Pricing of $12 Million Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the pricing of an underwritten public offering of 52,173,913 shares of its common stock. The public offering price of each share of comm
GlobeNewswire · 07/29 13:05
Sunesis under pressure on equity offering
Seeking Alpha · 07/29 04:00
Sunesis Pharma readies equity offering
Seeking Alpha · 07/28 20:57
Is Sunesis Pharmaceuticals (SNSS) Stock Outpacing Its Medical Peers This Year?
Is (SNSS) Outperforming Other Medical Stocks This Year?
Zacks · 07/23 15:30
Sunesis Pharmaceuticals Provides Corporate Update
GlobeNewswire · 07/07 21:01
Sunesis Pharma announces 30% cut in headcount
Seeking Alpha - Article · 07/07 20:09
Sunesis Pharma Reports Will Cut Workforce By ~30%
Benzinga · 07/07 20:01
66 Biggest Movers From Thursday
Gainers GEE Group, Inc. (NYSE: JOB) shares climbed 199.9% to close at $1.54 on Thursday after the company eliminated over $47 million in debt and mezzanine financing.
Benzinga · 07/06 09:18
Hedge Funds Are Selling Sunesis Pharmaceuticals, Inc. (SNSS)
Insider Monkey · 07/06 01:55
Oppenheimer Downgrades Sunesis Pharmaceuticals to Perform
Oppenheimer downgrades Sunesis Pharmaceuticals (NASDAQ:SNSS) from Outperform to Perform.
Benzinga · 06/24 09:41
Webull provides a variety of real-time SNSS stock news. You can receive the latest news about Sunesis Pharma through multiple platforms. This information may help you make smarter investment decisions.
About SNSS
Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of targeted inhibitors for the treatment of hematologic and solid cancers. The Company’s lead programs are Vecabrutinib, a selective non-covalent inhibitor of Bruton’s Tyrosine Kinase (BTK) inhibitors is in Phase Ib/II clinical trial. The Company is also developing SNS-510, a phosphoinositide dependent protein kinase 1 (PDK1) inhibitor and TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. The Company also offers Vosaroxin, an anticancer quinolone derivative (AQD), which is used for the treatment of acute myeloid leukemia (AML).